Bio-Path Holdings (FRA:IBP0) Total Stockholders Equity : €-2.40 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Bio-Path Holdings Total Stockholders Equity?

Bio-Path Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2025 was €-2.40 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Bio-Path Holdings's Book Value per Share for the quarter that ended in Mar. 2025 was €-0.42. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Bio-Path Holdings's Debt-to-Equity for the quarter that ended in Mar. 2025 was -0.12.

Bio-Path Holdings Total Stockholders Equity Historical Data

The historical data trend for Bio-Path Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings Total Stockholders Equity Chart

Bio-Path Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

12.39

22.53

13.38

0.40

0.15

Bio-Path Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															-2.42	1.20	-0.64	0.15	-2.40

Bio-Path Holdings (FRA:IBP0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Bio-Path Holdings's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-2.395	-	0)	/	5.768
	=	-0.42

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Bio-Path Holdings's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.291	+	0)	/	-2.395
	=	-0.12

Bio-Path Holdings Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Path Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (FRA:IBP0) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

BPTH:USA

Address

4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401

Website

https://www.biopathholdings.com

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Bio-Path Holdings Headlines

No Headlines